possibility of working in an international environment with interesting projects on the cutting edge of gene therapy, leukemogenesis and vectorology. Please see scientific goals for additional information. For
Associate Chairman, Dep. of Ped. Oncology, Dana-Farber Cancer Institute: ‘Gene therapy in monogenic diseases, a platform for gene editing in the clinic‘ 11.05.2016 - REBIRTH colloquium ( 5 pm c.t., Lecture [...] p.m.,c.t., lecture hall G) Juan A. Bueren, Ph.D., Head of the Hematopoietic Gene Therapy Division, CIEMAT, Madrid, Spain: Gene Therapy and Cell Reprogramming in Fanconi Anemia 21.06.2010, Special lecture [...] Uhr im Hörsaal Q) ‘The future is here! The next generation of AAV vector as a foundation of cell and gene therapeutics of the future’ Prof. Leszek Lisowski, Translational Vectorology Research Unit, Children’s
2003; 13(2): 133-8 Bock O, Serinsöz E, Neusch M, Schlué J, Kreipe H: The Polycythaemia rubra vera-1 gene is constitutively expressed by bone marrow cells and does not discriminate Polycythaemia vera from [...] Marwedel M, Musholt TJ: Frequency of mutations and loss of heterozygosity of the tumor suppressor gene PTEN in sporadic follicular thyroid carcinomas: does PTEN play a role in carcinogenesis? Langenbecks [...] Kreipe HH, Pfeifer GP, Schlegelberger B, Dammann R: Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 2003; 22(12): 1866-71 Schultheiss D, Badalyan R, Pilatz A, Gabouev
die zugrundeliegende genetische Mutation getroffen werden. Mittlerweile konnten Mutationen in >695 Genen identifiziert werden, die eine genetische Nierenerkrankung auslösen können. In Kooperation mit dem
Institute for Toxicology and Experimental Medicine, the Universities of Dresden and Aarhus (Denmark), Gene Center in München, the Institute of Protein Research (Russian Academy of Science), the synchrotron
Zellebene geschaffen: das Single Cell and Spatial Omics Analysis Centre (SiCSAC) und das Centre for Gene and Cell Therapy (CGaCT). Da die zukünftige Präzisionsmedizin nur auf einem soliden Fundament aus
Ferreira de Figueiredo (Transfusion Medicine) Project: Correction of monogenetic kidney diseases using a gene therapeutic approach Aavani Biju Sindhu INDIA; Sindhu.Aavani @ mh-hannover.de Supervisor: Prof. Dr [...] Felix @ mh-hannover.de Supervisor: Prof. Dr. Axel Schambach (Experimental Hematology) Project: Novel gene therapy strategies for inherited inner ear defects Lena Willmer GERMANY; lena.willmer @ item.fraunhofer
Robert @ mh-hannover.de Supervisor: Prof. Dr. Axel Schambach (Experimental Hematology) Project: Novel gene and immunotherapeutic approaches for the treatment of cervical cancer Pegah Rahmati IRAN Rahmati.Pegah [...] Pegah @ mh-hannover.de Supervisor: Prof. Dr. Britte Eiz-Vesper (Transfusion Medicine) Project: Gene-regulated EBV-specific T cells for personalized adoptive immunotherapy Final exam November 2024 Sonia
Institute of Experimental Hematology Project: Stem and progenitor cells for disease modeling and gene therapy of hearing loss Final exam November 2024 Christian Melcher GERMANY Melcher.Christian @ mh-hannover [...] Axel Schambach, Insitute of Experimental Haematology, Project: Development and validation of novel gene therapeutic approaches for correction of and protection from hearing loss Final exam June 2024 Dimyana
UKE Hamburg (Laufzeit: 1.07.2010 – 31.06.2011) DFG (KFG 123) Teilprojekt 3: Kompartiment-bezogene Gen- und Proteinexpression im Frühstadium der Bronchiolitis obliterans nach Lungentransplantation D. Steinemann [...] Schambach, Michael Ott, Hans R. Schöler, Tobias Cantz für die Arbeit: Generation of Healthy Mice from Gene-Corrected Disease-Specific Induced Pluripotent Stem Cells, erschienen in PLoS Biol 9(7), 2011 2015